C-reactive protein provides superior prognostic accuracy than the IMDC risk model in renal cell carcinoma treated with Atezolizumab/Bevacizumab

C-reactive protein provides superior prognostic accuracy than the IMDC risk model in renal cell carcinoma treated with Atezolizumab/Bevacizumab

BackgroundImmune checkpoint inhibitors (ICIs) is the main treatment option for patients with metastatic renal cell carcinoma (mRCC); however, significant heterogeneity in response is commonly observed. This study aimed to evaluate the ability of C-reactive protein (CRP) to predict overall survival (...

Full description

Bibliographic Details
Main Authors: Ahmad Y. Abuhelwa, Joaquim Bellmunt, Ganessan Kichenadasse, Ross A. McKinnon, Andrew Rowland, Michael J. Sorich, Ashley M. Hopkins
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Oncology
Subjects:
C-reactive protein
renal cell carcinoma
survival prognosis
immunotherapy
IMDC model
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.918993/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.918993/full

Similar Items